South Street Advisors LLC Sells 130 Shares of Zoetis Inc. (NYSE:ZTS)

South Street Advisors LLC cut its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 8.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 1,457 shares of the company’s stock after selling 130 shares during the period. South Street Advisors LLC’s holdings in Zoetis were worth $237,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Atlantic Edge Private Wealth Management LLC raised its stake in shares of Zoetis by 482.8% in the 4th quarter. Atlantic Edge Private Wealth Management LLC now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 140 shares during the period. Rakuten Securities Inc. raised its stake in shares of Zoetis by 5,533.3% in the 4th quarter. Rakuten Securities Inc. now owns 169 shares of the company’s stock valued at $28,000 after purchasing an additional 166 shares during the period. Darwin Wealth Management LLC acquired a new stake in shares of Zoetis in the 3rd quarter valued at about $31,000. Dunhill Financial LLC raised its stake in shares of Zoetis by 80.6% in the 3rd quarter. Dunhill Financial LLC now owns 168 shares of the company’s stock valued at $33,000 after purchasing an additional 75 shares during the period. Finally, Asset Planning Inc acquired a new stake in shares of Zoetis in the 4th quarter valued at about $58,000. Institutional investors and hedge funds own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The stock was sold at an average price of $166.14, for a total transaction of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares in the company, valued at $1,868,244.30. The trade was a 9.71 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 326 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $170.00, for a total value of $55,420.00. Following the sale, the executive vice president now owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This represents a 2.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 1,862 shares of company stock worth $312,254 over the last quarter. Company insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have issued reports on ZTS. UBS Group began coverage on Zoetis in a research note on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target on the stock. StockNews.com raised Zoetis from a “hold” rating to a “buy” rating in a research report on Friday, March 7th. Piper Sandler lifted their target price on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. Morgan Stanley lowered their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. Finally, Leerink Partners began coverage on Zoetis in a research report on Monday, December 2nd. They issued an “outperform” rating and a $215.00 target price on the stock. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $215.90.

Zoetis Price Performance

Shares of NYSE ZTS opened at $165.39 on Tuesday. The business’s 50 day moving average price is $166.82 and its two-hundred day moving average price is $175.97. The company has a market cap of $74.06 billion, a PE ratio of 30.24, a price-to-earnings-growth ratio of 2.78 and a beta of 0.94. The company has a quick ratio of 1.08, a current ratio of 1.75 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a twelve month low of $144.80 and a twelve month high of $200.33.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 13th. The company reported $1.40 earnings per share for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The firm had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, analysts predict that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.21%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s dividend payout ratio is presently 36.56%.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.